Lacidipine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: April 10, 2026🚩 Report this page

Lacidipine

Dihydropyridine Derivatives

GB MHRA

Drug class: Dihydropyridine Derivatives
Availability: See label
Markets covered: 1
Products on record: 12

Overview

Lacidipine is an active pharmaceutical ingredient in the Dihydropyridine Derivatives group (C08CA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	12	April 10, 2026

GBUnited Kingdom· MHRA

12 products

Uses

GBOfficial regulatory label· revised January 10, 2025[1]

Lacidipine is indicated for the treatment of essential hypertension either alone or in combination with other antihypertensive agents, including ß-adrenoceptor antagonists, diuretics, and ACE-inhibitors.

How to take

Sources & citations

[1]MHRA (UK) · PL331550021 · revised January 10, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised January 10, 2025[1]

Data from large clinical studies (internal and published) are used to determine the frequency of very common to uncommon side effects Very common ≥1/10 Common ≥ 1/100, <1/10 Uncommon ≥ 1/1000, <1/100 Rare ≥ 1/10000, <1/1000 Very rare <1/10000 Not known Cannot be estimated from the available data Lacidipine is generally well tolerated.
Some individuals may experience minor side effects which are related to its known pharmacological action of peripheral vasodilation. Such effects, indicated by a hash (#), are usually transient and usually disappear with continued administration of Lacidipine at the same dosage.
Pysichiatric disorders Depression very rare Nervous system disorders Dizziness# common Headache# common Tremor very rare Cardiac disorders Palpitations# common Tachycardia common Syncope uncommon Angina pectoris uncommon As with other dihydropyridines aggravation of underlying angina pectoris has been reported in a small number of individuals, especially at the start of treatment.
This is more likely to happen in patients with symptomatic ischaemic heart disease. Lacidipine should be discontinued under medical supervision in patients who develop unstable angina. Vascular disorders Flushing# common Hypotension uncommon Gastrointestinal disorders Abdominal discomfort common Nausea common Gingival hyperplasia uncommon Skin and subcutaneous tissue disorders Rash common Erythema common Pruritus common Angioedema rare Urticaria rare Musculoskeletal and connective tissue disorders Muscle cramps rare Renal and urinary disorders Polyuria common General disorders and administration site conditions Asthenia common Oedema# common Investigations: Reversible increase in alkaline phosphatase (sometimes clinically significant increases) common Reporting of suspected adverse reaction Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard

GBOfficial regulatory label· Warnings and precautions· revised January 10, 2025[1]

) the use of the product is contraindicated. 4 Special warnings and precautions for use In specialised studies lacidipine has been shown not to affect the spontaneous function of the SA node or to cause prolonged conduction within the AV node.
However, the theoretical potential for a calcium antagonist to affect the activity of the SA and AV nodes should be noted, and therefore lacidipine should be used with caution in patients with pre-existing abnormalities in the activity of the SA and AV nodes.
As has been reported with other dihydropyridine calcium channel antagonists, lacidipine should be used with caution in patients with congenital or documented acquired QT prolongation. g. g. terfenadine). As with other calcium antagonists, lacidipine should be used with caution in patients with poor cardiac reserve.
There is no evidence that lacidipine is useful for secondary prevention of myocardial infarction. The efficacy and safety of lacidipine tablets in the treatment of malignant hypertension has not been established. Lacidipine should be used with caution in patients with impaired liver function because antihypertensive effect may be increased.
There is no evidence that lacidipine impairs glucose tolerance or alters diabetic control. This product contains Lactose Monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations